Table 3.

Signs and Symptoms, Laboratory Abnormalities, New Diagnoses, and Lipid Results in Trial 1.^*

Variable	Nevirapine (N = 121)	Ritonavir-Boosted Lopinavir (N = 120)	Total (N = 241)	Unadjusted P Value‡
Grade 3 or higher sign or symptom — no. (%)†	17 (14)	13 (11)	30 (12)	0.56
General (pain, fatigue, weight loss, fever) — no.	9	7	16
Gastrointestinal (diarrhea, nausea, or vomiting) — no.	5	3	8
Cough or dyspnea — no.	2	3	5
Cardiovascular dysfunction — no.	2	1	3
Hepatic — no.	1	0	1
Grade 3 or higher laboratory abnormality — no. (%)†	32 (26)	26 (22)	58 (24)	0.45
Creatinine >1.8 times upper limit of normal	1	2	3
Sodium >154 or <125 mmol/liter	3	5	8
Potassium >6.5 or <2.5 mmol/liter	1	2	3
Liver enzymes	13	4	17
Aspartate aminotransferase >5 times upper limit of normal	6	3	9
Alanine aminotransferase >5 times upper limit of normal	10	2	12
Total bilirubin >2.5 times upper limit of normal	2	0	2
Hematologic abnormality	12	16	28
Platelets count <50,000/mm3	0	1	1
Hemoglobin <7.5 g/dl	3	5	8
Absolute neutrophil count <750/mm3	10	11	21
No. of participants with new diagnoses	73	75	148	0.79
Change in lipids from baseline to 48 wk (mg/dl)
Total cholesterol	21.0±3.3	25.1±3.0		0.35
HDL cholesterol	17.6±1.7	10.7±1.5		0.002
LDL cholesterol	6.7±2.9	13.1±2.6		0.10
Triglycerides	−14.1±5.4	16.5±8.6		0.006

^*Plus–minus values are means ±SE. Participants may have had more than one event.

^†Grading was performed with the use of the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, December 2004.

^‡P values for the comparison between the two treatment groups are shown. Those for the changes in lipids were calculated by means of the linear regression model; all other P values were obtained with the use of Fisher’s exact test.